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Background-—Dietary guidelines support intake of polyunsaturated fatty acids (PUFAs) in ﬁsh and vegetable oils. However, some
controversy remains about beneﬁts of PUFAs, and most prior studies have relied on self-reported dietary assessment in relatively
homogeneous populations.
Methods and Results-—In a multiethnic cohort of 2837 US adults (whites, Hispanics, African Americans, Chinese Americans),
plasma phospholipid PUFAs were measured at baseline (2000–2002) using gas chromatography and dietary PUFAs estimated
using a food frequency questionnaire. Incident cardiovascular disease (CVD) events (including coronary heart disease and stroke;
n=189) were prospectively identiﬁed through 2010 during 19 778 person-years of follow-up. In multivariable-adjusted Cox models,
circulating n-3 eicosapentaenoic acid and docosahexaenoic acid were inversely associated with incident CVD, with extreme-
quartile hazard ratios (95% CIs) of 0.49 for eicosapentaenoic acid (0.30 to 0.79; Ptrend=0.01) and 0.39 for docosahexaenoic acid
(0.22 to 0.67; Ptrend<0.001). n-3 Docosapentaenoic acid (DPA) was inversely associated with CVD in whites and Chinese, but not in
other race/ethnicities (P-interaction=0.01). No signiﬁcant associations with CVD were observed for circulating n-3 alpha-linolenic
acid or n-6 PUFA (linoleic acid, arachidonic acid). Associations with CVD of self-reported dietary PUFA were consistent with those
of the PUFA biomarkers. All associations were similar across racial-ethnic groups, except those of docosapentaenoic acid.
Conclusions-—Both dietary and circulating eicosapentaenoic acid and docosahexaenoic acid, but not alpha-linolenic acid or n-6
PUFA, were inversely associated with CVD incidence. These ﬁndings suggest that increased consumption of n-3 PUFA from
seafood may prevent CVD development in a multiethnic population. (J Am Heart Assoc. 2013;2:e000506 doi: 10.1161/JAHA.
113.000506)
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C
urrent dietary guidelines emphasize increasing consump-
tion of omega-3 (n-3) and omega-6 (n-6) long-chain
polyunsaturated fatty acids (PUFAs), found in ﬁsh and
vegetable oils, as a healthy substitute for saturated fatty
acids.
1,2 These recommendations are based on the beneﬁcial
effects of PUFAs on blood cholesterol and blood pressure, as
well as epidemiologic and clinical trial evidence suggesting
cardiovascular beneﬁts of PUFA consumption.
3–6 However, a
number of important questions remain unanswered. First,
most prior observational studies have evaluated associations
with self-reported PUFA intake, which may be inﬂuenced by
reporting bias and limited by nutrient database information.
The use of objective biomarkers of these fatty acids minimizes
reporting bias and also allows direct investigation of individual
circulating fatty acids. Yet few prior studies have evaluated
both dietary and circulating PUFA biomarkers. Second, recent
randomized, controlled trials of ﬁsh oil supplements in high-
risk patients have generally shown null results,
3 raising
concerns for true cardiovascular disease (CVD) beneﬁts of n-3
PUFAs. In addition, whereas meta-analyses of prospective
cohorts and of older clinical trials have seen lower CVD risk
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ORIGINAL RESEARCHwith higher consumption of n-6 PUFAs, largely linoleic acid
(LA),
4,6 concerns remain regarding the health risks of this
PUFA, for example, because of concern that LA and its
metabolite arachidonic acid (AA) may increase inﬂammation
and thrombosis.
7 Yet very few studies have assessed how
objective biomarkers of LA or AA relate to CVD risk. Finally,
evidence for cardiovascular effects of alpha-linolenic acid
(ALA), the plant-derived n-3 PUFA, and docosapentaenoic acid
(DPA), a long-chain n-3 PUFA of metabolic origin, remains
limited and inconclusive.
8,9 Notably, most prior evidence on
PUFAs and CVD was also based on studies in racially
homogeneous populations, which could have limited general-
izability to more diverse groups. To address these key gaps in
knowledge, we evaluated associations between both circulat-
ing biomarker and dietary n-3 and n-6 PUFAs and incident
CVD events in the Multi-Ethnic Study of Atherosclerosis
(MESA).
Methods
Study Design
MESA is a prospective cohort study designed to investigate
risk factors associated with subclinical cardiovascular disease
across race/ethnicities. MESA recruited 6814 participants in
6 US study centers (38% white, 28% African American, 22%
Hispanic, and 12% Chinese American) aged 45 to 84 years at
baseline (2000–2002) who were free of clinical CVD at that
time.
10 Health information was assessed during cohort
examinations in 2002–2003, 2004–2005, 2005–2007, and
2010–2011 and follow-up calls. Protocols were approved by
local institutional review boards, and all participants gave
written informed consent. Plasma phospholipid fatty acids
were measured at baseline in a subset of 2880 participants,
randomly selected from within each race/ethnic stratum to
provide similar proportions of participants from each group. In
this study, we included participants whose plasma phospho-
lipid fatty acids measurements and follow-up information were
available (n=2837). For dietary PUFA analysis, we further
excluded participants whose dietary data did not meet quality
control checks
11 (n=390) and those taking ﬁsh oil supple-
ments (n=118), which resulted in a subset with 2372
participants.
Measurement of Biochemical Variables
Fasting blood samples were collected at baseline examination
and subsequently processed and stored according to the
study protocol.
10,12 Plasma phospholipid fatty acids were
measured in MESA because of their correlation with key
dietary fatty acids, including n-3 and n-6 PUFAs, and with fatty
acid content in tissue membranes.
13 Individual phospholipid
fatty acids were extracted from EDTA plasma using a
chloroform/methanol extraction method,
13 and subsequently
separated from cholesterol esters, triglycerides, and free fatty
acids by thin-layer chromatography. Individual phospholipid
fatty acids were derivatized to methyl esters and detected by
gas chromatography ﬂame ionization. Phospholipid fatty acid
measurements were expressed as a percentage of total fatty
acids. Our primary focus of interest was n-3 and n-6 PUFAs
(ALA, eicosapentaenoic acid [EPA], DPA, docosahexaenoic
acid [DHA], EPA+DPA+DHA, LA, AA, LA+AA). For each fatty
acid, the automated (computer software) limit of detection
was 0.03%. Interassay coefﬁcents of variation were 13.5%
(ALA), 7.6% (EPA), 8.3% (DPA), 8.5% (DHA), 6.8% (LA), and
7.4% (AA).
Dietary Assessment and Other Covariates
Usual dietary intake over the previous year was assessed at
baseline using a Block-type,
14 120-item food frequency
questionnaire, modiﬁed to include Chinese foods.
15 Nutrient
intake was estimated for each food frequency questionnaire
item using the Nutrition Data System for Research (NDS-R
database; Nutrition Coordinating Center, Minneapolis, MN).
Criterion validity of macronutrient intake estimates has been
evaluated using baseline plasma lipid measurements.
16
Information on medical history, medication use, demo-
graphics, and smoking status was collected at baseline using
interviewer-administered and self-completed questionnaires.
Physical activity was assessed using a validated questionnaire
designed to assess time and frequency of various physical
activities.
17
CVD Risk Factors and Biomarkers of
Inﬂammation
Resting seated blood pressure was measured 3 times using a
Dinamap model Pro 100 automated oscillometric sphygmo-
manometer (Critikon). The mean of the last 2 measurements
was used in the analysis. Triglyceride was measured in EDTA
plasma using Triglyceride GB reagent (Roche Diagnostics).
Total cholesterol was measured in EDTA plasma using a
cholesterol oxidase method (Roche Diagnostics). After pre-
cipitation of non-high-density lipoprotein cholesterol (non-
HDL-C) with Mg/dextran, HDL cholesterol was measured
using the same method. Low-density lipoprotein cholesterol
(LDL-C) was calculated in plasma specimens having a
triglyceride value <4.52 mmol/L using the formula of Friede-
wald et al.
18 Anthropometric measurements were performed
using standard procedures. Plasma interleukin-6 (IL-6) was
measured by ultrasensitive ELISA (Quantikine HS Human IL-6
Immunoassay; R&D Systems). Plasma C-reactive protein (CRP)
was measured with a particle-enhanced immunonephelometric
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Behring). Tumor necrosis factor-a soluble receptor 1 (sTNF-
R1) was measured using an ultrasensitive ELISA assay
(Quantikine Human sTNF RI Immunoassay; R&D Systems,
Minneapolis, MN).
Diagnosis of CVD Incidence
Information on new CVD events was collected during each
cohort examination and every 9 to 12 months during follow-
up calls to each participant. Self-reported events were
conﬁrmed by medical record abstractions, death certiﬁcates,
autopsy reports, and/or obituaries. Medical records were
obtained for 98% of reported hospitalized events and 95% of
outpatient procedures.
19 Selected cardiovascular diagnoses
and procedures were reviewed by a medical end-points
committee. Total CVD events comprised myocardial infarc-
tion, resuscitated cardiac arrest, coronary heart disease
(CHD) death, other atherosclerotic death, angina, stroke,
stroke death, or other CVD death. CHD events comprised
myocardial infarction, resuscitated cardiac arrest, CHD death,
and angina. We also assessed “hard” total CVD, that is,
excluding angina. A standard protocol was used to classify
events and assign incident dates based on available
records.
20,21
Statistical Analysis
We estimated partial Spearman correlation between plasma
phospholipidfattyacidsandplasmaphospholipidfattyacidand
plant- andseafoodsources adjustingforage (years), sex,race/
ethnicity, and energy intake (kcal/day). We used linear
regression with robust variance estimators to assess associ-
ations of each circulating PUFA with CVD risk factors. For
prospective analyses, we used Cox proportional hazards to
estimate thehazardratio (HR)ofincident CVD,withtimeatrisk
untiltheﬁrstCVDevent,death,orlastfollow-upin2009–2010.
Associations with each dietary and circulating fatty acid were
evaluatedinquartilesandcontinuouslyperinterquartilemedian
range. We found no evidence of violation of the assumptions
underlying the proportional hazard models on the basis of the
Schoenfeldresidualsandofsigniﬁcancetestoftime-dependent
covariates included in Cox models (ie, interactions of the
predictors and a function of follow-up time). In addition, we
found no evidence of nonlinear associations between each
PUFA and the outcomes of interest based on restricted cubic
spline analysis.
22 We used serial models adjusting for potential
confounders selected on the basis of biologic interest and/or
well-established relationships with CVD risk. Linear trend was
tested by assigning the median value in each quartile to
participants and assessing this variable continuously. We
imputed missing covariate data (<2% for most lifestyle factors;
8%to12%fordietaryfactors)usingsingleimputation(SASproc
MI) based on age, sex, race/ethnicity, education, physical
activity, body mass index, smoking status, LDL-cholesterol,
HDL-cholesterol, cholesterol-lowering medication use, and
diabetes mellitus; results were similar when we used multiple
imputation or excluded missing values. We evaluated potential
effectmodiﬁcationbyage,sex,andrace/ethnicity.Wefoundno
evidence of evidence of a threshold or nonlinear associations
between each circulating PUFA biomarker and CVD risk. All P
values were 2 sided, with P<0.05 indicating statistical signif-
icance. All analyses were conducted using SAS version 9.3.
Results
At baseline, the average (SD) age was 61.5 (10.2) years, with
similar proportion of whites (n=724), African Americans
(n=697), Hispanics (n=705), and Chinese Americans
(n=711), and 46.8% were male (Table 1). The mean (SD)
plasma phospholipid concentrations of n-3 and n-6 fatty acids
ranged from 0.18% (0.08%) for ALA to 21.4% (3.4%) for LA.
Multivariate adjusted correlations amongst circulating sea-
food–n-3 PUFAs were moderate and positive, with correlation
coefﬁcients (r) ranging from 0.36 to 0.62 (Table 2), whereas
circulating n-6 PUFA showed overall moderate inverse
correlations amongst themselves and with n-3 PUFA. For
example, circulating AA was inversely correlated with circu-
lating ALA (r=0.34; Table 2). Dietary estimates of seafood-
derived fatty acids showed moderate positive correlations
with corresponding circulating PUFA, with r ranging from 0.41
to 0.46, whereas dietary plant-derived PUFAs were weakly
correlated with circulating fatty acids (r between 0.05 and
0.13).
When comparing participants in extreme quartiles of total
circulating seafood n-3 PUFAs (Table 3), those with higher
phospholipid seafood n-3 PUFAs were older, were more likely
to be Chinese American, had lower body mass index,
consumed more fruits and vegetables and less red meat,
and were more likely to take lipid-lowering medications. On
the other hand, participants with higher circulating n-6 PUFAs
were younger, were less physically active, had lower con-
sumption of whole grains, ﬁsh, and fruits and vegetables, and
were less likely to take lipid-lowering medications when
compared with those in the lowest quartile of circulating n-6
PUFAs.
Cross-Sectional Associations of Circulating
Seafood-Derived n-3 PUFAs With CVD Risk
Factors
In multivariate-adjusted analyses, circulating EPA was posi-
tively associated with LDL-C (Table 4) and inversely associ-
ated with IL-6, CRP, and s-TNF-R1. Circulating EPA was not
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or total:HDL-C. Similarly, circulating DPA was not associated
with blood pressure; however, it was inversely associated with
inﬂammatory markers IL-6 and CRP, but not sTNF-R1. In
contrast, circulating DPA showed overall harmful associations
with plasma lipids. For example, phospholipid DPA was
positively associated with triglycerides, LDL-C, and total:HDL-
C and inversely associated with HDL-C. Associations with
circulating DHA were similar to those of circulating EPA,
except for an inverse trend toward lower plasma triglycerides
and an inverse association with HDL-C. Overall, circulating
seafood n-3 PUFAs showed beneﬁcial associations with
markers of inﬂammation, mixed associations with plasma
lipids, and no association with blood pressure (Table 4).
Cross-Sectional Associations of Circulating n-3
ALA and n-6 PUFA With CVD Risk Factors
Circulating ALA was positively associated with plasma trigly-
cerides, inversely associated with LDL-C, and CRP, and
showed a trend toward higher plasma HDL-C (Ptrend=0.08;
Table 4) and higher sTNF-R1 (Ptrend=0.08). Circulating ALA
Table 1. Baseline Characteristics of 2837 US Adults in MESA
Whites (n=724) African Americans (n=697) Hispanics (n=705) Chinese (n=711) All (n=2837)
Age, y 61.4 (10.5) 61.5 (9.8) 61 (10.1) 62.3 (10.3) 61.5 (10.2)
Sex, % male 47.1 45.5 46.2 48.3 46.8
Education, % some college degree 78.0 69.7 33.9 59.3 60.3
Current smoking, % 15.6 18.9 15.0 5.3 13.7
Alcohol intake, g/day 8.5 (14.3) 3.2 (6.8) 3 (9) 1.4 (6.6) 4.1 (10.1)
Body mass index, kg/m
2 27.8 (5.3) 30.1 (5.8) 29.6 (5.1) 24 (3.3) 27.9 (5.5)
Physical activity, MET-min/week 2617.2 (3004.1) 2823.2 (3344.3) 2065.1 (2539.5) 1736.7 (1950.8) 2309.8 (2790)
Prevalent diabetes, % 5.9 16.8 17.3 12.5 13.1
Antihypertensive medication use, % 32.0 48.8 32.9 28.5 35.5
Lipid-lowering medication use, % 15.9 17.5 14.8 14.0 15.5
Dietary supplement use, % 36.7 48.2 41.1 36.6 40.6
Dietary factors, servings/day
Whole grains 0.7 (0.6) 0.6 (0.5) 0.5 (0.5) 0.3 (0.5) 0.5 (0.5)
Meat 0.4 (0.3) 0.4 (0.4) 0.4 (0.5) 0.4 (0.4) 0.4 (0.4)
Seafood 0.3 (0.3) 0.4 (0.4) 0.2 (0.3) 0.4 (0.4) 0.3 (0.3)
Total fruits and vegetables 3.4 (2.1) 3.5 (2.3) 3.3 (2.3) 4.4 (2.5) 3.6 (2.3)
Dietary ALA, g/day 1.1 (0.6) 1.1 (0.7) 1.0 (0.6) 0.6 (0.4) 1.0 (0.6)
Dietary LA, g/day 9.8 (5.9) 10.6 (8.0) 8.7 (6.3) 7.3 (4.3) 9.0 (6.3)
Dietary AA, g/day 0.11 (0.08) 0.14 (0.10) 0.11 (0.08) 0.11 (0.07) 0.12 (0.08)
Dietary EPA, mg/day 40 (44) 57 (66) 32 (39) 51 (46) 45 (50)
Dietary DPA, mg/day 20 (21) 25 (25) 15 (16) 19 (17) 20 (20)
Dietary DHA, mg/day 78 (69) 104 (93) 64 (59) 82 (62) 82 (73)
Circulating PUFAs, % of total phospholipid fatty acids
ALA 0.19 (0.11) 0.16 (0.06) 0.17 (0.08) 0.18 (0.07) 0.18 (0.08)
LA 20.9 (3) 19.8 (2.8) 21.7 (3.2) 23.3 (3.6) 21.4 (3.4)
AA 12.1 (2.2) 13.8 (2.3) 11.7 (2.6) 10.5 (2.2) 12.0 (2.6)
EPA 1.0 (0.7) 1.0 (0.8) 0.7 (0.5) 1.3 (1.3) 1.0 (0.9)
DPA 1.0 (0.2) 1.0 (0.2) 0.9 (0.2) 1.0 (0.2) 1.0 (0.2)
DHA 3.7 (1.4) 4.6 (1.4) 3.4 (1.2) 5.1 (1.5) 4.2 (1.6)
Values are mean (SD) for continuous variables and percent for categorical variables. AA indicates arachidonic acid; ALA, alpha-linolenic acid; DHA, docosahexaenoic acid; DPA,
docosapentaenoic acid; EPA, eicosapentaenoic acid; LA, linoleic acid; MESA, Multi-Ethnic Study of Atherosclerosis; MET, metabolic equivalent; PUFA, polyunsaturated fatty acid; SD,
standard deviation.
DOI: 10.1161/JAHA.113.000506 Journal of the American Heart Association 4
Omega-3 and Omega-6 PUFA and CVD Incidence in MESA de Oliveira Otto et al
O
R
I
G
I
N
A
L
R
E
S
E
A
R
C
HT
a
b
l
e
2
.
C
o
r
r
e
l
a
t
i
o
n
s
*
B
e
t
w
e
e
n
P
l
a
s
m
a
C
i
r
c
u
l
a
t
i
n
g
P
U
F
A
s
a
n
d
S
e
l
f
-
R
e
p
o
r
t
e
d
P
U
F
A
I
n
t
a
k
e
i
n
M
E
S
A
(
n
=
2
8
3
7
)
P
h
o
s
p
h
o
l
i
p
i
d
A
L
A
,
%
T
o
t
a
l
F
A
P
h
o
s
p
h
o
l
i
p
i
d
L
A
,
%
T
o
t
a
l
F
A
P
h
o
s
p
h
o
l
i
p
i
d
A
A
,
%
T
o
t
a
l
F
A
P
h
o
s
p
h
o
l
i
p
i
d
L
A
+
A
A
,
%
T
o
t
a
l
F
A
P
h
o
s
p
h
o
l
i
p
i
d
E
P
A
,
%
T
o
t
a
l
F
A
P
h
o
s
p
h
o
l
i
p
i
d
D
P
A
,
%
T
o
t
a
l
F
A
P
h
o
s
p
h
o
l
i
p
i
d
D
H
A
,
%
T
o
t
a
l
F
A
P
h
o
s
p
h
o
l
i
p
i
d
E
P
A
+
D
P
A
+
D
H
A
,
%
T
o
t
a
l
F
A
P
l
a
n
t
F
o
o
d
s
,
†
s
e
r
v
i
n
g
s
/
d
a
y
S
e
a
f
o
o
d
,
‡
s
e
r
v
i
n
g
s
/
d
a
y
D
i
e
t
a
r
y
A
L
A
,
g
/
d
a
y
0
.
0
5
0
.
0
8
0
.
0
6
0
.
3
7
0
.
0
9
D
i
e
t
a
r
y
L
A
,
g
/
d
a
y
0
.
1
3
0
.
1
7

0
.
0
6
0
.
1
4
0
.
0
5
D
i
e
t
a
r
y
A
A
,
g
/
d
a
y

0
.
0
5
0
.
0
5
0
.
0
5
0
.
1
0
0
.
1
9
0
.
1
7

0
.
0
4
0
.
3
5
S
u
m
o
f
d
i
e
t
a
r
y
L
A
+
A
A
,
g
/
d
a
y
0
.
1
3
0
.
1
7

0
.
0
6
0
.
1
4
0
.
0
5
D
i
e
t
a
r
y
E
P
A
,
g
/
d
a
y

0
.
0
6

0
.
0
4

0
.
1
1
0
.
3
4
0
.
1
2
0
.
4
6
0
.
4
5
0
.
1
2
0
.
8
9
D
i
e
t
a
r
y
D
P
A
,
g
/
d
a
y

0
.
0
9

0
.
1
2
0
.
3
3
0
.
1
2
0
.
4
1
0
.
4
1
0
.
1
4
0
.
8
0
D
i
e
t
a
r
y
D
H
A
,
g
/
d
a
y

0
.
0
7

0
.
0
9
0
.
3
1
0
.
0
9
0
.
4
3
0
.
4
2
0
.
1
0
0
.
8
1
S
u
m
o
f
d
i
e
t
a
r
y
E
P
A
+
D
P
A
+
D
H
A
,
g
/
d
a
y

0
.
0
2

0
.
0
7

0
.
1
1
0
.
3
3
0
.
1
1
0
.
4
5
0
.
4
4
0
.
1
2
0
.
8
5
P
h
o
s
p
h
o
l
i
p
i
d
A
L
A
,
%
t
o
t
a
l
F
A
0
.
2
8

0
.
3
4
0
.
1
6
0
.
0
5

0
.
0
5
0
.
0
8

0
.
0
2
P
h
o
s
p
h
o
l
i
p
i
d
L
A
,
%
t
o
t
a
l
F
A

0
.
5
3
0
.
6
3

0
.
3
5

0
.
3
8

0
.
2
4

0
.
3
0

0
.
1
3
P
h
o
s
p
h
o
l
i
p
i
d
A
A
,
%
t
o
t
a
l
F
A
0
.
2
5
0
.
0
6
0
.
1
4
0
.
0
6
0
.
0
3
S
u
m
o
f
p
h
o
s
p
h
o
l
i
p
i
d
L
A
+
A
A
,
%
t
o
t
a
l
F
A

0
.
3
5

0
.
3
2

0
.
2
3

0
.
2
8

0
.
1
3
P
h
o
s
p
h
o
l
i
p
i
d
E
P
A
,
%
t
o
t
a
l
F
A
0
.
5
8
0
.
6
2
0
.
7
7
0
.
1
4
0
.
3
0
P
h
o
s
p
h
o
l
i
p
i
d
D
P
A
,
%
t
o
t
a
l
F
A
0
.
3
6
0
.
5
1
0
.
0
5
0
.
1
1
P
h
o
s
p
h
o
l
i
p
i
d
D
H
A
,
%
t
o
t
a
l
F
A
0
.
9
7
0
.
1
7
0
.
3
9
S
u
m
o
f
p
h
o
s
p
h
o
l
i
p
i
d
E
P
A
+
D
P
A
+
D
H
A
,
%
t
o
t
a
l
F
A
0
.
1
7
0
.
3
9
P
l
a
n
t
f
o
o
d
s
,
†
s
e
r
v
i
n
g
s
/
d
a
y
0
.
1
8
A
A
i
n
d
i
c
a
t
e
s
a
r
a
c
h
i
d
o
n
i
c
a
c
i
d
;
A
L
A
,
a
l
p
h
a
-
l
i
n
o
l
e
n
i
c
a
c
i
d
;
D
H
A
,
d
o
c
o
s
a
h
e
x
a
e
n
o
i
c
a
c
i
d
;
D
P
A
,
d
o
c
o
s
a
p
e
n
t
a
e
n
o
i
c
a
c
i
d
;
E
P
A
,
e
i
c
o
s
a
p
e
n
t
a
e
n
o
i
c
a
c
i
d
;
L
A
,
l
i
n
o
l
e
i
c
a
c
i
d
;
M
E
S
A
,
M
u
l
t
i
-
E
t
h
n
i
c
S
t
u
d
y
o
f
A
t
h
e
r
o
s
c
l
e
r
o
s
i
s
;
P
U
F
A
,
p
o
l
y
u
n
s
a
t
u
r
a
t
e
d
f
a
t
t
y
a
c
i
d
.
*
P
a
r
t
i
a
l
S
p
e
a
r
m
a
n
c
o
r
r
e
l
a
t
i
o
n
s
a
d
j
u
s
t
i
n
g
f
o
r
a
g
e
,
s
e
x
,
r
a
c
e
/
e
t
h
n
i
c
i
t
y
,
a
n
d
e
n
e
r
g
y
i
n
t
a
k
e
.
O
n
l
y
s
t
a
t
i
s
t
i
c
a
l
l
y
s
i
g
n
i
ﬁ
c
a
n
t
c
o
r
r
e
l
a
t
i
o
n
s
a
t
t
h
e
0
.
0
5
s
i
g
n
i
ﬁ
c
a
n
c
e
l
e
v
e
l
a
r
e
s
h
o
w
n
.
†
P
l
a
n
t
f
o
o
d
s
o
u
r
c
e
s
2
3
:
a
l
m
o
n
d
s
,
w
a
l
n
u
t
s
,
p
e
c
a
n
s
,
o
t
h
e
r
n
u
t
s
;
s
u
n
ﬂ
o
w
e
r
,
p
i
n
y
o
n
,
o
t
h
e
r
s
e
e
d
s
;
p
e
a
n
u
t
s
,
p
e
a
n
u
t
b
u
t
t
e
r
;
m
i
s
o
s
o
u
p
o
r
s
a
u
c
e
w
i
t
h
s
o
y
b
e
a
n
p
a
s
t
e
;
s
o
y
m
i
l
k
;
p
i
n
t
o
,
b
l
a
c
k
,
b
a
k
e
d
,
b
u
t
t
e
r
,
o
r
r
e
d
b
e
a
n
s
,
p
o
r
k
a
n
d
b
e
a
n
s
,
b
l
a
c
k
-
e
y
e
d
p
e
a
s
;
b
r
o
c
c
o
l
i
,
c
a
b
b
a
g
e
,
c
a
u
l
i
ﬂ
o
w
e
r
,
b
r
u
s
s
e
l
s
s
p
r
o
u
t
s
,
s
a
u
e
r
k
r
a
u
t
,
k
i
m
c
h
i
;
t
o
s
s
e
d
s
a
l
a
d
w
i
t
h
s
p
i
n
a
c
h
,
r
o
m
a
i
n
e
,
o
r
d
a
r
k
g
r
e
e
n
s
,
c
o
o
k
e
d
s
p
i
n
a
c
h
,
t
u
r
n
i
p
g
r
e
e
n
s
,
c
o
l
l
a
r
d
s
;
t
o
s
s
e
d
s
a
l
a
d
w
i
t
h
i
c
e
b
e
r
g
o
r
l
i
g
h
t
g
r
e
e
n
l
e
t
t
u
c
e
;
g
r
e
e
n
b
e
a
n
s
,
p
e
a
s
,
s
n
o
w
p
e
a
s
;
p
e
a
,
l
e
n
t
i
l
,
b
l
a
c
k
b
e
a
n
,
p
o
t
a
j
e
s
o
u
p
s
;
c
o
r
n
,
h
o
m
i
n
y
;
o
a
t
m
e
a
l
,
o
t
h
e
r
h
o
t
c
e
r
e
a
l
(
g
r
i
t
s
,
c
r
e
a
m
o
f
w
h
e
a
t
,
m
u
s
h
,
c
o
n
g
e
e
)
;
b
r
o
w
n
o
r
w
i
l
d
r
i
c
e
;
w
h
i
t
e
,
M
e
x
i
c
a
n
,
o
r
s
t
i
c
k
y
r
i
c
e
;
a
v
o
c
a
d
o
,
g
u
a
c
a
m
o
l
e
;
s
t
r
a
w
b
e
r
r
i
e
s
,
b
l
u
e
b
e
r
r
i
e
s
,
o
t
h
e
r
b
e
r
r
i
e
s
;
b
u
t
t
e
r
,
m
a
r
g
a
r
i
n
e
,
o
r
o
i
l
o
n
v
e
g
e
t
a
b
l
e
s
,
r
i
c
e
,
o
r
p
o
t
a
t
o
e
s
,
m
a
r
g
a
r
i
n
e
o
r
m
a
y
o
n
n
a
i
s
e
o
n
b
r
e
a
d
o
r
r
o
l
l
s
;
s
t
i
r
-
f
r
i
e
d
t
o
f
u
o
r
t
e
m
p
e
h
w
i
t
h
v
e
g
e
t
a
b
l
e
s
;
d
e
s
s
e
r
t
m
a
d
e
w
i
t
h
t
o
f
u
.
‡
S
e
a
f
o
o
d
:
f
r
i
e
d
ﬁ
s
h
o
r
ﬁ
s
h
s
a
n
d
w
i
c
h
,
f
r
i
e
d
s
h
r
i
m
p
,
c
a
l
a
m
a
r
i
;
s
h
r
i
m
p
,
l
o
b
s
t
e
r
,
c
r
a
b
,
o
y
s
t
e
r
s
,
m
u
s
s
e
l
s
(
n
o
t
f
r
i
e
d
)
;
t
u
n
a
,
s
a
l
m
o
n
,
s
a
r
d
i
n
e
s
(
i
n
c
l
u
d
i
n
g
s
a
s
h
i
m
i
o
r
s
u
s
h
i
)
;
o
t
h
e
r
b
r
o
i
l
e
d
,
s
t
e
a
m
e
d
,
b
a
k
e
d
,
o
r
r
a
w
ﬁ
s
h
(
t
r
o
u
t
,
s
o
l
e
,
h
a
l
i
b
u
t
,
p
o
k
e
,
g
r
o
u
p
e
r
)
.
DOI: 10.1161/JAHA.113.000506 Journal of the American Heart Association 5
Omega-3 and Omega-6 PUFA and CVD Incidence in MESA de Oliveira Otto et al
O
R
I
G
I
N
A
L
R
E
S
E
A
R
C
HTable 3. Baseline Characteristics of 2837 US Adults With PUFA Biomarker Measurements in the Multi-Ethnic Study of
Atherosclerosis by Quartiles of Total Phospholipid Seafood-Derived PUFAs
Quartiles of Phospholipid EPA+DPA+DHA
1234
Age, y 60.4 (10.4) 61.9 (10.2) 61.8 (9.9) 62.1 (10.2)
Sex, % male 48.8 46.1 48.4 48.7
Race/ethnicity
Whites, % 35.2 31.0 19.0 19.2
African Americans, % 12.4 24.7 34.6 27.4
Hispanics, % 45.3 27.0 15.8 9.6
Chinese, % 7.1 17.3 30.6 43.7
Education, % some college degree 54.0 60.1 63.4 67.0
Current smoking, % 20.9 14.7 12.4 7.3
Alcohol intake, g/day 4.6 (10.1) 3.8 (8.9) 4.6 (12.1) 3.2 (8.8)
Body mass index, kg/m
2 29 (5.5) 28.6 (5.9) 27.3 (5.1) 26.5 (5)
Physical activity, MET-min/week 2217.1 (2883.9) 2262.4 (2724.5) 2367.8 (2636.7) 2394.6 (2904.5)
Prevalent diabetes, % 14.6 10.9 13.0 12.3
Antihypertensive medication use, % 30.8 35.7 41.0 33.8
Lipid-lowering medication use, % 10.2 15.3 17.8 18.1
Dietary factors
Whole grains, servings/day 0.5 (0.5) 0.5 (0.5) 0.5 (0.6) 0.5 (0.5)
Meat, servings/day 0.5 (0.5) 0.4 (0.4) 0.4 (0.3) 0.4 (0.4)
Total fruits and vegetables, servings/day 3.1 (2.1) 3.5 (2.4) 3.8 (2.3) 4.2 (2.5)
PUFA plant sources, servings/day 2.6 (1.7) 2.7 (1.7) 2.7 (1.5) 2.8 (1.5)
PUFA seafood sources, servings/day 0.1 (0.2) 0.2 (0.3) 0.2 (0.2) 0.3 (0.3)
Transfat, % energy 0.9 (0.3) 0.8 (0.3) 0.7 (0.4) 0.6 (0.3)
Saturated fat, % energy 11.2 (3.2) 10.3 (3.2) 9.4 (3.1) 8.7 (2.9)
Monounsaturated fat, % energy 12.6 (2.7) 12 (2.9) 11.6 (2.9) 11 (3)
Polyunsaturated fat, % energy 6.2 (1.8) 6.2 (1.9) 6.3 (1.8) 6.2 (1.7)
Carbohydrate, % energy 51.9 (8.2) 53.2 (9.2) 53.8 (9.1) 54.4 (9.5)
Protein, % energy 15.3 (3) 15.9 (3.3) 16.4 (3.3) 17.5 (3.6)
Dietary ALA, g/day 1.1 (0.6) 1 (0.6) 0.9 (0.6) 0.8 (0.5)
Dietary LA, g/day 10.5 (6.8) 9.4 (7.3) 8.6 (5.4) 7.9 (5.2)
Dietary AA, g/day 0.12 (0.09) 0.12 (0.08) 0.12 (0.08) 0.12 (0.08)
Dietary EPA, mg/day 28 (37) 41 (44) 47 (42) 67 (63)
Dietary DPA, mg/day 13 (15) 18 (18) 20 (17) 28 (25)
Dietary DHA, mg/day 62 (61) 76 (67) 84 (61) 108 (88)
Circulating PUFAs
ALA, % of total phospholipid fatty acids 0.18 (0.07) 0.17 (0.07) 0.18 (0.07) 0.18 (0.11)
LA, % of total phospholipid fatty acids 22.7 (3.1) 21.5 (3.2) 21.2 (3.2) 20.3 (3.6)
AA, % of total phospholipid fatty acids 11.4 (2.3) 12.6 (2.6) 12.5 (2.7) 11.5 (2.5)
EPA, % of total phospholipid fatty acids 0.48 (0.17) 0.62 (0.22) 0.84 (0.31) 1.92 (1.35)
DPA, % of total phospholipid fatty acids 0.83 (0.17) 0.9 (0.18) 0.96 (0.17) 1.14 (0.25)
DHA, % of total phospholipid fatty acids 2.5 (0.5) 3.5 (0.4) 4.6 (0.5) 6.3 (1.1)
AA indicates arachidonic acid; ALA, alpha-linolenic acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; LA, linoleic acid; MET, metabolic equivalent;
PUFA, polyunsaturated fatty acid.
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HTable 4. Multivariable-Adjusted Cross-Sectional Associations of Circulating PUFAs With CVD Risk Factors in MESA
n
Quartiles of Plasma Phospholipid Fatty Acids
Ptrend 1234
EPA, % total FA (median) 0.39 0.6 0.86 1.62
Systolic BP, mm Hg 2834 125.7 (0.8) 125.8 (0.7) 125.8 (0.7) 126.7 (0.8) 0.34
Diastolic BP, mm Hg 2834 71.7 (0.4) 71.5 (0.4) 72.1 (0.4) 72.3 (0.4) 0.22
Triglycerides, mg/dL 2833 130.3 (3.7) 139.4 (3.5) 142.3 (3.1) 130.7 (3) 0.44
HDL-C, mg/dL 2833 49.6 (0.5) 50.8 (0.4) 51.2 (0.5) 50.7 (0.5) 0.33
LDL-C, mg/dL 2788 115.3 (1.2) 116.8 (1.1) 116.3 (1.2) 119.8 (1.2) 0.01
Total:HDL-C 2833 4.1 (0.05) 4.1 (0.04) 4.1 (0.04) 4.1 (0.04) 0.99
IL-6, pg/mL 2774 1.6 (0.05) 1.6 (0.05) 1.5 (0.04) 1.4 (0.04) 0.01
CRP, mg/L 2826 4.2 (0.3) 3.6 (0.2) 3.3 (0.2) 3.3 (0.2) 0.06
sTNF-R1, pg/mL 2834 1418 (16) 1363 (16) 1359 (15) 1320 (13) <0.0001
DPA, % total FA (median) 0.72 0.88 1.01 1.21
Systolic BP, mm Hg 2834 126.3 (0.7) 126.8 (0.8) 124.4 (0.7) 126.6 (0.7) 0.75
Diastolic BP, mm Hg 2834 72 (0.3) 72 (0.4) 71.6 (0.4) 72 (0.4) 0.92
Triglycerides, mg/dL 2833 131.2 (3.4) 131.7 (3.6) 135.6 (3.1) 145.2 (3.1) 0.003
HDL-C, mg/dL 2833 51.4 (0.5) 50.3 (0.4) 51 (0.4) 49.4 (0.5) 0.01
LDL-C, mg/dL 2788 112.8 (1.2) 115 (1.1) 120.6 (1.1) 120 (1.2) <0.0001
Total:HDL-C 2833 4 (0.05) 4 (0.04) 4.1 (0.04) 4.3 (0.04) <0.0001
IL-6, pg/mL 2774 1.6 (0.05) 1.5 (0.04) 1.5 (0.04) 1.4 (0.04) <0.0001
CRP, mg/L 2826 4.2 (0.2) 3.7 (0.2) 3.5 (0.2) 2.8 (0.1) <0.0001
sTNF-R1, pg/mL 2834 1344 (15) 1380 (17) 1354 (14) 1389 (17) 0.11
DHA, % total FA (median) 2.5 3.5 4.5 6.0
Systolic BP, mm Hg 2834 126.8 (0.8) 125.2 (0.7) 126 (0.8) 126.1 (0.8) 0.80
Diastolic BP, mm Hg 2834 71.9 (0.4) 71.5 (0.3) 72.2 (0.4) 72 (0.4) 0.68
Triglycerides, mg/dL 2833 142.1 (5.1) 135.4 (2.6) 133.6 (2.7) 131.6 (3.1) 0.08
HDL-C, mg/dL 2833 51.7 (0.5) 50.2 (0.5) 50.5 (0.5) 50 (0.5) 0.07
LDL-C, mg/dL 2788 116 (1.4) 117.2 (1.1) 115.8 (1.2) 119.1 (1.3) 0.13
Total:HDL-C 2833 4.1 (0.05) 4.1 (0.04) 4.1 (0.04) 4.1 (0.04) 0.34
IL-6, pg/mL 2774 1.5 (0.05) 1.6 (0.05) 1.5 (0.05) 1.4 (0.04) 0.01
CRP, mg/L 2826 3.2 (0.2) 4.1 (0.2) 3.8 (0.3) 3.3 (0.2) 0.47
sTNF-R1, pg/mL 2834 1409 (17) 1358 (15) 1374 (17) 1323 (15) 0.003
EPA+DPA+DHA, % total FA (median) 3.9 5.0 6.3 8.7
Systolic BP, mmHg 2834 126.3 (0.8) 125.6 (0.7) 126.1 (0.8) 125.9 (0.8) 0.84
Diastolic BP, mmHg 2834 71.8 (0.4) 71.7 (0.3) 72.1 (0.4) 72.1 (0.4) 0.59
Triglycerides, mg/dL 2833 137 (4.5) 137.1 (2.9) 138.6 (2.8) 129.9 (3) 0.13
HDL-C, mg/dL 2833 51.9 (0.5) 49.9 (0.5) 50.3 (0.5) 50.2 (0.5) 0.15
LDL-C, mg/dL 2788 114.9 (1.3) 117.9 (1.2) 115.2 (1.2) 120.2 (1.3) 0.013
Total:HDL-C 2833 4 (0..05) 4.2 (0.04) 4.1 (0.04) 4.1 (0.04) 0.28
IL-6, pg/mL 2774 1.6 (0.05) 1.6 (0.05) 1.5 (0.05) 1.3 (0.04) <0.0001
CRP, mg/L 2826 3.6 (0.2) 3.9 (0.2) 3.5 (0.2) 3.4 (0.2) 0.42
sTNF-R1, pg/mL 2834 1389.2 (16.3) 1385 (16.6) 1370.5 (16.8) 1317 (14) 0.001
Plant n-3 PUFA
ALA, % total FA (median) 0.11 0.15 0.19 0.25
Systolic BP, mm Hg 2834 125.9 (0.6) 125.7 (0.8) 125.6 (0.7) 126.8 (0.8) 0.25
Continued
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HTable 4. Continued
n
Quartiles of Plasma Phospholipid Fatty Acids
Ptrend 1234
Diastolic BP, mm Hg 2834 71.5 (0.3) 72.5 (0.4) 71.6 (0.3) 72.2 (0.4) 0.36
Triglycerides, mg/dL 2833 126.6 (2.3) 132.6 (3.4) 139.1 (3.4) 146.9 (4.4) <0.0001
HDL-C, mg/dL 2833 50 (0.4) 50.7 (0.5) 50.6 (0.4) 51.2 (0.5) 0.08
LDL-C, mg/dL 2788 118.6 (1.1) 119.3 (1.3) 115.9 (1.1) 114 (1.2) 0.002
Total:HDL-C 2833 4.1 (0.04) 4.1 (0.05) 4.1 (0.04) 4.1 (0.05) 0.22
IL-6, pg/mL 2774 1.5 (0.04) 1.5 (0.05) 1.5 (0.04) 1.5 (0.05) 0.92
CRP, mg/L 2826 4.0 (0.2) 3.5 (0.2) 3.5 (0.2) 3.2 (0.2) 0.02
sTNF-R1, pg/mL 2834 1350 (13) 1355 (17) 1375 (15) 1385 (17) 0.08
n-6 PUFA
LA, % total FA (median) 17.6 20.2 22.4 25.2
Systolic BP, mm Hg 2834 126.7 (0.7) 126.7 (0.7) 125.4 (0.7) 125.2 (0.8) 0.09
Diastolic BP, mm Hg 2834 72.2 (0.4) 72.1 (0.4) 71.8 (0.3) 71.5 (0.4) 0.17
Triglycerides, mg/dL 2833 146.2 (3) 136.3 (2.7) 129.7 (2.8) 130.3 (4.7) 0.001
HDL-C, mg/dL 2833 50.8 (0.5) 50.2 (0.4) 50.1 (0.4) 51.3 (0.5) 0.53
LDL-C, mg/dL 2788 115.4 (1.3) 118 (1.2) 118.3 (1.1) 116.4 (1.2) 0.55
Total:HDL-C 2833 4.1 (0.04) 4.1 (0.04) 4.1 (0.04) 4.1 (0.05) 0.69
IL-6, pg/mL 2774 1.4 (0.04) 1.5 (0.04) 1.6 (0.04) 1.5 (0.05) 0.07
CRP, mg/L 2826 4.2 (0.3) 3.4 (0.2) 3.5 (0.2) 3.2 (0.2) 0.01
sTNF-R1, pg/mL 2834 1346.7 (14.9) 1349.5 (13) 1376.1 (17.5) 1390 (16) 0.04
AA, % total FA (median) 9.0 11.0 12.8 15.1
Systolic BP, mm Hg 2834 126 (0.8) 125.7 (0.7) 126.1 (0.7) 126.1 (0.8) 0.79
Diastolic BP, mm Hg 2834 72 (0.4) 71.6 (0.4) 72.1 (0.4) 71.9 (0.4) 0.89
Triglycerides, mg/dL 2833 145.2 (4.7) 132.1 (2.9) 134.8 (3) 130.5 (2.7) 0.012
HDL-C, mg/dL 2833 48.9 (0.5) 50.8 (0.5) 50 (0.5) 52.6 (0.5) <0.0001
LDL-C, mg/dL 2788 117 (1.2) 118.6 (1.2) 117.1 (1.2) 115.4 (1.3) 0.23
Total:HDL-C 2833 4.3 (0.05) 4.1 (0.04) 4.1 (0.04) 3.9 (0.04) <0.0001
IL-6, pg/mL 2774 1.6 (0.05) 1.5 (0.04) 1.5 (0.04) 1.5 (0.05) 0.060
CRP, mg/L 2826 3.5 (0.2) 3.1 (0.2) 3.5 (0.2) 4.2 (0.3) 0.03
sTNF-R1, pg/mL 2834 1435.8 (17.2) 1349.3 (14.6) 1343 (15.6) 1335 (16) <0.0001
LA+AA, % total FA (median) 30.1 32.6 34.4 36.7
Systolic BP, mmHg 2834 127.3 (0.7) 126.6 (0.7) 125.8 (0.7) 124.3 (0.7) 0.004
Diastolic BP, mmHg 2834 72.6 (0.4) 71.9 (0.4) 71.8 (0.3) 71.3 (0.4) 0.01
Triglycerides, mg/dL 2833 150.6 (3.1) 143.2 (3.6) 128.6 (2.7) 119.9 (3.6) <0.0001
HDL-C, mg/dL 2833 49.2 (0.5) 50.2 (0.5) 50.9 (0.4) 52 (0.5) <0.0001
LDL-C, mg/dL 2788 116.8 (1.2) 118 (1.1) 117.4 (1.2) 115.9 (1.2) 0.54
Total:HDL-C 2833 4.2 (0.04) 4.2 (0.04) 4.1 (0.04) 4 (0.04) <0.0001
IL-6, pg/mL 2774 1.5 (0.04) 1.5 (0.05) 1.5 (0.04) 1.5 (0.04) 0.54
CRP, mg/L 2826 3.7 (0.2) 3.6 (0.2) 3.7 (0.2) 3.3 (0.2) 0.25
sTNF-R1, pg/mL 2834 1389.3 (14.7) 1349.5 (15.4) 1369.7 (15) 1354 (16) 0.20
Values are mean (SE). Means are adjusted for age (years), sex, race/ethnicity (white, African American, Hispanic, Chinese), education (<high school, high school, some college, college
graduate), ﬁeld center, smoking status (never, former, current) and pack-years of cigarette smoking, prevalent diabetes (yes, no), alcohol use (g/day), physical activity (active and inactive
leisure, MET-min/week), and body mass index. (kg/m
2). AA indicates arachidonic acid; ALA, alpha-linolenic acid; BP, blood pressure; CRP, C-reactive protein; CVD, cardiovascular disease;
DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; HDL-C, high-density lipoprotein cholesterol; IL, interleukin; LA, linoleic acid; LDL-C, low-density
lipoprotein cholesterol; MESA, Multi-Ethnic Study of Atherosclerosis; MET, metabolic equivalent; PUFA, polyunsaturated fatty acids SE, standard error of the mean; sTNF-R1, tumor necrosis
factor-a soluble receptor 1.
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blood pressure, total:HDL-C, or IL-6. Similarly, circulating n-6
PUFAs showed no associations with blood pressure, except
for a trend toward lower systolic blood pressure for higher
circulating LA levels. LA and AA were inversely associated
with triglycerides and showed no associations with LDL-C;
however, phospholipid AA, but not LA, showed beneﬁcial
associations with HDL-C and total:HDL-C (Table 4).
All statistically signiﬁcant associations remained un-
changed after additional adjustment for other dietary factors,
including intakes of fruits, vegetables, and whole grains; or for
use of lipid-lowering and anti-hypertensive medication (not
shown).
Prospective Associations of Seafood n-3 PUFA
With Incident CVD
A total of 189 new CVD cases were identiﬁed during 19 778
person-years of follow-up from 2000 to 2010. After adjust-
ment for potential confounders, circulating EPA and DHA,
but not DPA, were inversely associated with lower risk of
CVD incidence, with a 51% lower risk in the highest quartile
of EPA (HR [95% CI], 0.49 [0.30 to 0.82]), and 61% lower
risk in the highest quartile of DHA (HR [95% CI], 0.39 [0.22
to 0.67]) (Table 5). Findings were similar when evaluating
fatty acids continuously (HR [95% CI] for each interquartile
median range difference increase of circulating PUFAs was
0.59 [0.40 to 0.86]) for EPA, 0.71 [0.49 to 1.02] for DPA,
and 0.48 [0.30 to 0.75] for DHA). Findings of dietary
estimated seafood n-3 PUFA intake with incident CVD were
similar; however, associations were smaller and CIs wider,
consistent with high within-person variation in the dietary
measures.
Prospective Associations of ALA and n-6 PUFA
With Incident CVD
In contrast to favorable associations with seafood n-3 PUFA,
we found no statistically signiﬁcant associations between
biomarkers or self-reported measures of ALA or AA and
incident CVD in MESA (Table 6). Multivariate-adjusted HR
(95% CI) in the highest quartiles was 1.19 (0.79 to 1.78;
Ptrend=0.51) for phospholipid ALA, and 0.88 (0.55 to 1.41;
Ptrend=0.67) for circulating AA. On the other hand, we found
evidence of a trend toward increased CVD risk associated
with higher LA concentrations (HR [95% CI] in the highest
quartile, 1.75 [1.11 to 2.75; Ptrend=0.08]). This association
was not signiﬁcant for dietary LA or when circulating LA was
evaluated continuously. Overall, ﬁndings were similar for CHD
outcomes, although associations of circulating seafood-
derived PUFA with CHD outcomes were slightly stronger than
those of total CVD (Tables 7 and 8).
Sensitivity Analyses
Results did not change substantially when we restricted the
analysis to participants who were not taking ﬁsh oil supple-
ments and in similar analysis excluding angina. For example,
the multivariate-adjusted HR (95% CI) after excluding angina
(n=132 cases) was 0.40 (0.23 to 0.72; Ptrend=0.004) and 0.48
(0.25 to 0.93; Ptrend=0.02) for the highest quartiles of EPA and
DHA, respectively.
Inﬂuence of Potential Mediators
Further adjustment for factors that could be potential
mediators or confounders, including plasma triglycerides,
HDL-cholesterol, and LDL-cholesterol, use of lipid-lowering
medication, and baseline inﬂammation (plasma IL-6, CRP, and
sTNF-R1) did not appreciably alter our ﬁndings. For example,
HR (95% CI) of CVD in the highest quartiles was 0.46 (0.29 to
0.75) for circulating EPA and 0.38 (0.22 to 0.67) for DHA.
Heterogeneity by Sex and Race/Ethnicity
Associations of circulating n-3 and n-6 PUFAs with CVD
were similar across sex. For example, HR (95% CI) in the
highest quartiles of EPA was 0.39 (0.17 to 0.88) in women
and 0.58 (0.30 to 1.11) in men, whereas HR (95% CI) for
high DHA levels was 0.32 (0.12 to 0.87) in women and
0.41 (0.20 to 0.86) in men. Associations for each n-3 and
n-6 PUFA were also similar in each race/ethnic group,
except for circulating DPA. The multivariate-adjusted HR
(95% CI) for each interquartile range difference in circulat-
ing DPA levels was 0.46 (0.24 to 0.92) in whites, 0.27
(0.10 to 0.70) in Chinese, 1.51 (0.75 to 3.03) in African
Americans, and 1.33 (0.62 to 2.85) in Hispanics (P for
interaction=0.01; Table 9).
Discussion
In this large prospective cohort of multiethnic Americans,
higher circulating EPA andDHA were each inverselyassociated
withmarkersofinﬂammationandprospectivelyassociatedwith
lower CVD incidence. Circulating DPA, a fatty acid largely
derived from endogenous metabolism, was inversely associ-
ated with CVD events in whites and Chinese, but not in African
Americans and Hispanics. Conversely, circulating plant-derived
n-3 PUFA (ALA) was not associated with most CVD risk factors
or with CVD incidence. In addition, although higher total
circulating n-6 PUFAs were inversely associated with systolic
and diastolic blood pressure, plasma triglycerides, and total:
HDL-C ratio, there were no signiﬁcant associations between
total or individual n-6 PUFAs and CVD risk. When we evaluated
n-3 and n-6 dietary PUFAs, nearly all ﬁndings were generally
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HTable 5. Hazard Ratios (95% CIs) of Total CVD* by Sex-Speciﬁc Quartiles and Interquartile Median Range Units of Seafood n-3
PUFA in US Adults
Sex-Specific Quartiles of Plasma Phospholipid Fatty Acids (n=2837)
Ptrend
HR (95% CI) for
1-IQR
†—Unit
Difference in FA
Concentrations 12 3 4
Phospholipid EPA, % total FA (median) 0.40 0.60 0.86 1.62
n 732 711 695 699
Cases 66 48 47 28
Multivariate model
‡ REF 0.75 (0.51, 1.09) 0.84 (0.56, 1.25) 0.49 (0.30, 0.79) 0.01 0.59 (0.40, 0.86)
Phospholipid DPA, % total FA (median) 0.72 0.88 1.01 1.21
n 752 701 747 637
Cases 56 58 43 32
Multivariate model
‡ REF 1.05 (0.72, 1.53) 0.77 (0.51, 1.16) 0.75 (0.48, 1.18) 0.11 0.71 (0.49, 1.02)
Phospholipid DHA, % total FA (median) 2.5 3.5 4.5 6.0
n 694 738 693 712
Cases 59 61 46 23
Multivariate model
‡ REF 0.95 (0.65, 1.39) 0.70 (0.45, 1.08) 0.39 (0.22, 0.67) <0.001 0.50 (0.32, 0.78)
Phospholipid EPA+DPA +DHA, % total FA
(median)
3.9 5.0 6.3 8.7
n 736 688 713 700
Cases 63 59 40 27
Multivariate model
‡ REF 0.97 (0.67, 1.40) 0.64 (0.41, 1.00) 0.47 (0.28, 0.79) 0.002 0.46 (0.29, 0.72)
Sex-specific quartiles of dietary fatty acids (n=2372)
1 234
Dietary EPA, mg/day (median) 10 20 40 90
n 599 547 585 641
Cases 56 40 33 32
Multivariate model
‡ REF 0.94 (0.62, 1.42) 0.65 (0.42, 1.03) 0.60 (0.37, 0.98) 0.03 0.67 (0.46, 0.97)
Dietary DPA, mg/day (median) 4.0 10 19 39
n 622 618 559 573
Cases 53 50 30 28
Multivariate model
‡ REF 1.10 (0.74, 1.63) 0.67 (0.42, 1.07) 0.59 (0.35, 0.97) 0.02 0.70 (0.48, 1.02)
Dietary DHA, mg/day (median) 20 50 80 150
n 606 572 600 594
Cases 46 45 42 28
Multivariate model
‡ REF 0.98 (0.64, 1.49) 0.92 (0.59, 1.44) 0.60 (0.35, 1.02) 0.048 0.66 (0.44, 1.00)
Dietary EPA+DPA +DHA, mg/day
(median)
40 80 140 280
n 600 546 651 575
Cases 47 47 39 28
Multivariate model
‡ REF 1.16 (0.77, 1.75) 0.81 (0.52, 1.28) 0.64 (0.38, 1.09) 0.05 0.66 (0.44, 0.98)
BMI indicates body mass index; CHD, coronary heart disease; CI, conﬁdence interval; CVD, cardiovascular disease; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA,
eicosapentaenoic acid; MI, myocardial infarction; PUFA, polyunsaturated fatty acid.
*CHD events comprise MI, resuscitated cardiac arrest, deﬁnite and probable angina (if followed by revascularization), and CHD death.
†1-interquartile median ranges (IQR)=1.2 (phospholipid EPA), 0.49 (phospholipid DPA), 3.5 (phospholipid DHA), 4.8 (phospholipid EPA+DPA+DHA), 80 (dietary EPA), 35 (dietary DPA),
130 (dietary DHA) and 240 (dietary EPA+DPA+DHA).
‡Multivariate model: ﬁeld center, age (years), sex, race/ethnicity (Whites, African American, Hispanic, and Chinese), education (<high school, high school, >high school), cigarette smoking
(never, current or former smokers, and pack-years of cigarette smoking), alcohol (g/day), physical activity (active and inactive leisure in metabolic equivalents [min/week]), BMI (kg/m
2),
prevalent diabetes (yes/no), total energy intake (kcal/day), weekly dietary supplement use (yes/no), and hypertensive medication use (yes/no), fruits and vegetables (servings/day), ﬁber
(g/day), processed and unprocessed meat (servings/day), vitamin E (IU/day), saturated fat (% energy), and transfat intake (g/day).
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HTable 6. Hazard Ratios (95% CIs) of Total CVD* by Sex-Speciﬁc Quartiles and Interquartile Median Range Units of n-3 and n-6
PUFA in US Adults
Sex-Specific Quartiles of Plasma Phospholipid Fatty Acids (n=2837)
Ptrend
HR (95% CI) for
1-IQR
†—Unit
Difference in FA
Concentrations 12 3 4
Phospholipid ALA, % total FA (median) 0.11 0.15 0.19 0.25
n 883 569 757 628
Cases 63 37 46 43
Multivariate model
‡ REF 0.95 (0.63, 1.43) 0.92 (0.62, 1.35) 1.19 (0.79, 1.78) 0.51 1.03 (0.83, 1.28)
Phospholipid LA, % total FA (median) 17.6 20.2 22.4 25.2
n 714 697 718 708
Cases 45 56 38 50
Multivariate model
‡ REF 1.39 (0.93, 2.08) 0.95 (0.61, 1.48) 1.75 (1.11, 2.75) 0.08 1.35 (0.92, 1.97)
Phospholipid AA, % total FA (median) 9.0 11.0 12.8 15.1
n 705 724 702 706
Cases 41 47 52 49
Multivariate model
‡ REF 0.97 (0.63, 1.50) 1.06 (0.69, 1.63) 0.88 (0.55, 1.41) 0.67 0.90 (0.61, 1.32)
Phospholipid LA+AA, % total FA
(median)
30.1 32.6 34.4 36.7
n 710 712 714 701
Cases 41 58 43 47
Multivariate model
‡ REF 1.36 (0.90, 2.04) 1.03 (0.66, 1.60) 1.31 (0.84, 2.02) 0.44 1.22 (0.86, 1.74)
Sex-specific quartiles of dietary fatty acids (n=2372)
12 3 4
Dietary ALA, mg/day (median) 390 690 1020 1610
n 700 592 555 525
Cases 44 42 43 32
Multivariate model
§ REF 0.88 (0.56, 1.34) 0.94 (0.55, 1.59) 0.61 (0.29, 1.28) 0.20 0.69 (0.39, 1.22)
Dietary LA, mg/day (median) 3870 6230 9220 14 980
n 638 581 605 548
Cases 53 24 46 38
Multivariate model
§ REF 0.47 (0.28, 0.78) 0.87 (0.54, 1.41) 0.74 (0.38, 1.43) 0.81 0.83 (0.55, 1.25)
Dietary AA, mg/day (median) 40 80 120 200
n 605 530 667 570
Cases 40 36 42 43
Multivariate model
§ 0.96 (0.60, 1.53) 1.06 (0.66, 1.67) 1.26 (0.72, 2.20) 0.34 1.08 (0.71, 1.63)
Dietary LA+AA, mg/day (median) 4000 6300 9400 15 200
n 630 583 607 552
Cases 52 25 46 38
Multivariate model
§ REF 0.49 (0.30, 0.81) 0.87 (0.54, 1.41) 0.74 (0.38, 1.44) 0.77 1.14 (0.63, 2.05)
AA indicates arachidonic acid; ALA, alpha-linolenic acid; BMI, body mass index; CI, conﬁdence interval; CVD, cardiovascular disease; LA, linoleic acid; PUFA, polyunsaturated fatty acid.
*CHD events comprise MI, resuscitated cardiac arrest, deﬁnite and probable angina (if followed by revascularization), and CHD death.
†Interquartile median ranges (IQR): 0.14 (phospholipid ALA), 7.6 (phospholipid LA), 6.1 (phospholipid AA), 6.6 (phospholipid LA+AA), 1200 (dietary ALA), 11 100 (dietary LA), 160 (dietary
AA), 11 200 (dietary LA+AA).
‡Multivariate model: ﬁeld center, age (years), sex, race/ethnicity (Caucasian, African American, Hispanic and Chinese), education (<high school, high school, >high school), cigarette
smoking (never, current or former smokers, and pack-years of cigarette smoking), alcohol (g/day), physical activity (active and inactive leisure in metabolic equivalents per min/week), BMI
(kg/m
2), prevalent diabetes (yes/no), total energy intake (kcal/day),weekly dietary supplement use (yes/no) and hypertensive medication use (yes/no), fruits and vegetables (serving/
day), ﬁber (g/day), processed and unprocessed meat (serving/day), vitamin E (IU/day), saturated fat (% energy) and trans fat intake (g/day).
§This model included all variables listed in ‡, except dietary vitamin E.
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HTable 7. Hazard Ratios (and 95% Conﬁdence Intervals) of Total CHD* by Sex-Speciﬁc Quartiles and Interquartile Median Range
Units of Seafood-Derived PUFA in 2837 Adults
Sex-Specific Quartiles of Plasma Phospholipid Fatty Acids (n=2837)
Ptrend
HR (95% CI) for
1-IQR
†–Unit
Difference in FA
Concentrations 1 234
Phospholipid EPA, % total FA (median) 0.40 0.60 0.86 1.62
n 732 711 695 699
Cases 49 38 37 17
Multivariate plus dietary factors
‡ REF 0.82 (0.53, 1.26) 0.93 (0.59, 1.46) 0.42 (0.23, 0.75) 0.004 0.51 (0.31, 0.82)
Phospholipid DPA, % total FA (median) 0.72 0.88 1.01 1.21
n 752 701 747 637
Cases 41 43 33 24
Multivariate plus dietary factors
‡ REF 1.10 (0.71, 1.70) 0.84 (0.53, 1.35) 0.80 (0.48, 1.35) 0.29 0.71 (0.47, 1.09)
Phospholipid DHA, % total FA (median) 2.5 3.5 4.5 6.0
n 694 738 693 712
Cases 48 45 34 14
Multivariate plus dietary factors
‡ 0.87 (0.57, 1.34) 0.66 (0.4, 1.09) 0.29 (0.15, 0.58) 0.0002 0.43 (0.25, 0.82)
Phospholipid EPA+DPA +DHA, % total FA
(median)
3.9 5.0 6.3 8.7
n 736 688 713 700
Cases 50 42 30 19
Multivariate plus dietary factors
‡ REF 0.92 (0.60, 1.41) 0.66 (0.4, 1.10) 0.45 (0.25, 0.82) 0.006 0.40 (0.23, 0.69)
Sex-specific quartiles of dietary fatty acids (n=2392)
12 3 4
Dietary EPA, mg/day (median) 7.3 21 40 85
n 599 547 585 641
Cases 40 33 28 21
Multivariate plus dietary factors
‡ REF 1.12 (0.70, 1.80) 0.82 (0.50, 1.37) 0.61 (0.34, 1.10) 0.06 0.66 (0.43, 1.02)
Dietary DPA, Mg/day (median) 4.3 11 19 39
n 622 618 559 573
Cases 40 40 24 18
Multivariate plus dietary factors
‡ REF 1.19 (0.76, 1.86) 0.74 (0.50, 1.26) 0.54 (0.29, 0.99) 0.02 0.65 (0.41, 1.03)
Dietary DHA, mg/day (median) 24 49 80 150
n 606 572 600 594
Cases 34 34 36 18
Multivariate plus dietary factors
‡ REF 1.02 (0.63, 1.67) 1.12 (0.68, 1.86) 0.57 (0.30, 1.09) 0.09 0.64 (0.39, 1.05)
Dietary EPA+DPA +DHA, mg/day (median) 38 82 140 280
n 600 546 651 575
Cases 33 39 32 18
Multivariate plus dietary factors
‡ REF 1.39 (0.86, 2.23) 1.00 (0.60, 1.69) 0.64 (0.34, 1.22) 0.08
BMI indicates body mass index; CHD, coronary heart disease; CRP, C-reactive protein; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; HDL-C, high-
density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; PUFA, polyunsaturated fatty acid; sTNF-R1, tumor necrosis factor-a soluble receptor 1.
*CHD events comprise MI, resuscitated cardiac arrest, deﬁnite and probable angina (if followed by revascularization), and CHD death.
†One interquartile median range is 1.2 for phospholipid EPA, 0.49 for phospholipid DPA, 3.5 for phospholipid DHA, 4.8 for phospholipid EPA+DPA+DHA, 80 for dietary EPA, 35 for dietary
DPA, 130 for dietary DHA, and 240 for dietary EPA+DPA+DHA.
‡Multivariate model: ﬁeld center, age (years), sex, race/ethnicity (Caucasian, African American, Hispanic, and Chinese), education (<high school, high school, >high school), cigarette
smoking (never, current, or former smokers and pack-years of cigarette smoking), alcohol (g/day), physical activity (active and inactive leisure in metabolic equivalents [min/week]), BMI
(kg/m
2), prevalent diabetes (yes/no), total energy intake (kcal/day), weekly dietary supplement use (yes/no), hypertensive medication use (yes/no), fruits and vegetables (servings/day),
processed and unprocessed meat (servings/day), ﬁber (g/day), vitamin E (IU/day), saturated fat (% energy), and trans-fat intake (g/day).
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HTable 8. Hazard Ratios (and 95% Conﬁdence Intervals) of Total CHD* by Sex-Speciﬁc Quartiles and Interquartile Median Range
Units of n-3 and n-6 PUFAs in 2837 Adults
Sex-Specific Quartiles of Plasma Phospholipid Fatty Acids (n=2837)
Ptrend
HR (95% CI) for
1-IQR
†—Unit
Difference in FA
Concentrations 1 234
Phospholipid ALA, % total FA (median) 0.11 0.15 0.19 0.25
n 883 569 757 628
Cases 46 27 37 31
Multivariate plus dietary factors
‡ REF 0.93 (0.58, 1.51) 1.02 (0.65, 1.58) 1.18 (0.74, 1.91) 0.48 1.04 (0.83, 1.32)
Phospholipid LA, % total FA (median) 17.6 20.2 22.4 25.2
n 714 697 718 708
Cases 31 42 30 38
Multivariate plus dietary factors
‡ REF 1.47 (0.92, 2.37) 1.07 (0.64, 1.81) 1.88 (1.11, 3.19) 0.07 1.46 (0.94, 2.26)
Phospholipid AA, % total FA (median) 9.0 11.0 12.8 15.1
n 705 724 702 706
Cases 30 36 37 38
Multivariate plus dietary factors
‡ REF 1.01 (0.61, 1.65) 1.02 (0.62, 1.69) 0.99 (0.58, 1.69) 0.98 1.00 (0.64, 1.55)
Phospholipid LA+AA, % total FA (median) 30.1 32.6 34.4 36.7
n 710 712 714 701
Cases 30 40 30 41
Multivariate plus dietary factors
‡ REF 1.29 (0.80, 2.09) 1.01 (0.60, 1.69) 1.63 (1.00, 2.67) 0.10 1.47 (0.96, 2.17)
Sex-specific quartiles of dietary fatty acids (n=2372)
12 3 4
Dietary ALA, mg/day (median) 450 760 1080 1690
n 700 592 555 525
Cases 34 33 33 22
Multivariate plus dietary factors
‡§ REF 0.93 (0.55, 1.56) 0.99 (0.53, 1.83) 0.60 (0.25, 1.41) 0.24 0.67 (0.30, 1.31)
Dietary LA, mg/day (median) 3870 6230 9220 14 980
n 638 581 605 548
Cases 43 18 33 28
Multivariate plus dietary factors
‡ REF 0.45 (0.25, 0.80) 0.79 (0.45, 1.37) 0.71 (0.33, 1.51) 0.73 1.20 (0.60, 2.40)
Dietary AA, mg/day (median) 40 80 120 200
n 605 530 667 570
Cases 30 30 30 32
Multivariate plus dietary factors
‡ REF 1.08 (0.64, 1.84) 1.00 (0.58, 1.74) 1.30 (0.68, 2.48) 0.45 1.06 (0.67, 1.69)
Dietary LA+AA, mg/day (median) 4000 6300 9400 15 200
n 630 583 607 552
Cases 42 19 33 28
Multivariate plus dietary factors
‡ REF 0.48 (0.27, 0.85) 0.79 (0.45, 1.38) 0.72 (0.33, 1.53) 0.71 1.20 (0.60, 2.41)
AA indicates arachidonic acid; ALA, alpha-linolenic acid; BMI, body mass index; CHD, coronary heart disease; CVD, cardiovascular disease; DHA, docosahexaenoic acid; DPA,
docosapentaenoic acid; EPA, eicosapentaenoic acid; LA, linoleic acid; MI, myocardial infarction; PUFA, polyunsaturated fatty acid.
*CHD events comprise MI, resuscitated cardiac arrest, deﬁnite and probable angina (if followed by revascularization), and CVD death.
†One interquartile median range is 0.14 for phospholipid ALA, 1.2 for phospholipid EPA, 0.49 for phospholipid DPA, 3.5 for phospholipid DHA, 4.8 for phospholipid EPA+DPA+DHA, 80 for
dietary EPA, 35 for dietary DPA, 130 for dietary DHA, and 240 for dietary EPA+DPA+DHA. ‡Interquartile median ranges: 0.14 for phospholipid ALA, 7.6 for phospholipid LA, 6.1 for
phospholipid AA, 6.6 for phospholipid LA+AA, 1200 for dietary ALA, 11 100 for dietary LA, 160 for dietary AA, and 11 200 for dietary LA+AA.
‡Multivariate model: ﬁeld center, age (years), sex, race/ethnicity (Caucasian, African American, Hispanic, and Chinese), education (<high school, high school, >high school), cigarette
smoking (never, current, or former smoker and pack-years of cigarette smoking), alcohol (g/day), physical activity (active and inactive leisure in metabolic equivalents [min/week]), BMI
(kg/m2), prevalent diabetes (yes/no), total energy intake (kcal/day), weekly dietary supplement use (yes/no), hypertensive medication use (yes/no), processed and unprocessed meat
(servings/day), ﬁber (g/day), fruits and vegetables (servings/day), vitamin E (IU/day), saturated fat (% energy), and trans-fat intake (g/day).
§Included all variables listed in ‡, except dietary vitamin E.
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ﬁndings build and expand on prior studies investigating the
relationship between n-3 and n-6 PUFAs and CVD risk by
providing evidence from both biomarker and dietary fatty acids
in a large, prospective multiethnic cohort.
Several mechanisms may explain the favorable associa-
tions between EPA and DHA and CVD risk. In experimental
studies, higher n-3 PUFA levels alter cell membrane ﬂuidity
and receptor responses, regulate gene transcription, and
serve as metabolic precursors to potent anti-inﬂammatory
molecules.
9 These molecular effects may underlie their
demonstrated systemic and cardiac beneﬁts, such as on
inﬂammatory responses, autonomic control, vascular and
cardiac hemodynamics, endothelial function, blood lipids, and
possibly thrombosis.
9,24 The observed inverse associations
with inﬂammatory markers in the present study support both
previous observations
25,26 and recent experimental studies
suggesting anti-inﬂammatory effects of n-3 PUFA and their
downstream metabolites.
27 Our cross-sectional ﬁndings for
blood lipids are also broadly consistent with results from
clinical trials that demonstrated that EPA+DHA supplemen-
tation lowers triglyceride levels and slightly increases LDL-
cholesterol levels,
28,29 the latter being largely related to
increases in LDL particle size rather than particle number
(apolipoprotein B levels). In contrast, DPA was associated
with higher triglyceride levels; that DPA is not strongly
correlated with dietary intake may reﬂect endogenous
metabolism, and its lipid and metabolic effects are
understudied. Taken together, these results build on prior
studies and add new evidence of potential pathways for CVD
development.
Prospective associations of EPA and DHA are consistent
with previous studies. In a meta-analysis including >300 000
participants, the pooled relative risk (95% CI) of total CHD
for extreme quartiles of dietary seafood n-3 PUFA intake was
0.86 (0.75 to 0.97)
30; associations with CHD mortality were
stronger.
5 Fewer observational studies have evaluated
circulating biomarkers of seafood-PUFA and incident CVD,
mostly in white participants; these studies have generally
seen inverse associations with risk.
31–36 Our results in a
multiethnic cohort demonstrate, for the ﬁrst time to our
knowledge, the generalizability of these favorable associa-
tions across race/ethnicities. In contrast to these generally
consistent results from observational studies of dietary EPA
and DHA, the effects of ﬁsh oil supplements on CVD in
randomized, controlled trials have been mixed,
3 with older
trials showing beneﬁts and more recent studies showing no
signiﬁcant effects.
3 Heterogeneity in population characteris-
tics, background dietary ﬁsh consumption, and length of
follow-up may each contribute to these inconsistent ﬁndings
from different study designs. For example, prior evidence
suggests that risk reduction for CHD mortality is maximal
Table 9. Hazard Ratios (and 95% Conﬁdence Intervals) of
Total CVD for Circulating Seafood-Derived PUFAs in 2837 US
Adults According to Race/Ethnicity
HR (95% CI) per
IQR*, MV1
†
HR (95% CI) per
IQR*, MV2
‡
Phospholipid EPA
All 0.60 (0.41 to 0.87) 0.59 (0.40 to 0.86)
White 0.45 (0.22 to 0.92) 0.38 (0.18 to 0.79)
Chinese 0.49 (0.22 to 1.10) 0.57 (0.25 to 1.28)
African American 0.76 (0.40 to 1.47) 0.77 (0.40 to 1.50)
Hispanic 0.74 (0.28 to 1.92) 0.87 (0.34 to 2.22)
P-interaction 0.90 0.90
Phospholipid DPA
All 0.72 (0.50 to 1.03) 0.71 (0.49 to 1.02)
White 0.46 (0.24 to 0.92) 0.41 (0.21 to 0.82)
Chinese 0.27 (0.10 to 0.70) 0.30 (0.11 to 0.81)
African American 1.51 (0.75 to 3.03) 1.51 (0.74 to 3.09)
Hispanic 1.33 (0.62 to 2.85) 1.33 (0.61 to 2.90)
P-interaction 0.01 0.01
Phospholipid DHA
All 0.50 (0.32 to 0.78) 0.48 (0.30 to 0.75)
White 0.45 (0.20 to 1.01) 0.34 (0.15 to 0.81)
Chinese 0.30 (0.11 to 0.84) 0.37 (0.12 to 1.08)
African American 0.42 (0.17 to 1.04) 0.42 (0.17 to 1.05)
Hispanic 0.68 (0.25 to 1.84) 0.73 (0.25 to 2.13)
P-interaction 0.80 0.85
Phospholipid EPA+DPA+DHA
All 0.48 (0.30 to 0.75) 0.46 (0.29 to 0.72)
White 0.37 (0.16 to 0.86) 0.28 (0.12 to 0.68)
Chinese 0.31 (0.11 to 0.82) 0.37 (0.13 to 1.03)
African American 0.51 (0.21 to 1.26) 0.51 (0.20 to 1.27)
Hispanic 0.71 (0.25 to 2.00) 0.79 (0.26 to 2.38)
P-interaction 0.84 0.88
Total number of participants (cases) per racial/ethnic stratum: 724 (62) whites, 712 (28)
Chinese, 696 (48) African Americans, 705 (51) Hispanics. AA indicates arachidonic acid;
CI, conﬁdence interval; CVD, cardiovascular disease; DHA, docosahexaenoic acid; DPA,
docosapentaenoic acid; EPA, eicosapentaenoic acid; HR, hazard ratio; IQR, interquartile
median range; MV, multivariate model; PUFA, polyunsaturated fatty acid.
*One IQR is 1.2 for phospholipid EPA, 0.49 for phospholipid DPA, 3.5 for phospholipid
DHA, 4.8 for phospholipid EPA+DPA+DHA.
†Multivariate model: ﬁeld center, age (years), sex, race/ethnicity (Whites, African
Americans, Hispanics, and Chinese Americans), education (<high school, high school,
>high school), cigarette smoking (never, current, or former smokers and pack-years of
cigarette smoking), alcohol (g/day), physical activity (active and inactive leisure in
metabolic equivalents [min/week]), BMI (kg/m
2), prevalent diabetes (yes/no), total
energy intake (kcal/day), weekly dietary supplement use (yes/no), and hypertensive
medication use (yes/no).
‡Multivariate model 1+fruitsand vegetables (servings/day), ﬁber (g/day),processed and
unprocessedmeat(servings/day),vitaminE(IU/day),saturatedfat(%energy),andtransfat
intake (g/day).
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day EPA+DHA), with little to no additional beneﬁt at higher
levels of intake.
5 Thus, in more recent trials that included
populations with relatively high background ﬁsh consump-
tion, the addition of ﬁsh oil supplementation may have only
had a small impact on CVD, at least over only a few years.
Because few participants in MESA were taking ﬁsh oil
supplements, our results support the beneﬁts of higher
blood levels of n-3 PUFA across dietary levels of consump-
tion for primary prevention of CVD in multiethnic popula-
tions.
In contrast to EPA and DHA, associations between
circulating DPA and CVD risk were heterogeneous across
race/ethnicities. Consistent with earlier studies,
31,35 we
found weak associations between ﬁsh consumption and
phospholipid DPA, suggesting that endogenous metabolism
inﬂuences circulating DPA concentrations, for example, by
chain elongation and desaturation of EPA. Genetic variants of
enzymes involved in this metabolic conversion are associated
with DPA levels.
37 Furthermore, these genetic variants are
associated with altered inﬂammatory responses and risk of
CHD.
38 Whether race-speciﬁc genetic differences in n-3 PUFA
metabolism could explain the observed heterogeneity by race
in associations of circulating DPA with CVD deserves further
investigation. These results could also be due to chance. Our
ﬁndings support the need to understand the dietary and
metabolic determinants and cardiovascular effects of circu-
lating DPA in different ethnic groups.
Although ALA improved several CVD risk factors in
experimental studies,
39–41 we did not ﬁnd signiﬁcant associ-
ations between this plant-derived n-3 PUFA and CVD events.
Our ﬁndings are in line with a recent systematic review and
meta-analysis that identiﬁed substantial inconsistencies and
overall weak associations of dietary and biomarker ALA with
CVD risk in observational studies.
42 We also found no
evidence of inverse associations with CVD of circulating or
dietary LA or AA; these ﬁndings contrast with evidence from
meta-analyses of observational studies and clinical trials that
estimated a 10% to 13% reduction in incident CHD with
replacement of 5% energy from saturated fat with PUFAs.
4,6
Indeed, we found a nonsigniﬁcant trend toward higher CVD
risk with higher circulating LA, as also seen in older US
adults.
32 Differences in food sources of ALA and LA may at
least partly explain inconsistencies across prior studies. For
example, some of the largest sources of ALA and LA in the US
diet are reﬁned-grain breads, desserts, pizza, popcorn, french
fries, potato chips, burgers, and processed meats,
43,44
together accounting for 30% and 40% of ALA and LA intake,
respectively.
43,44 In contrast, most randomized trials used
vegetable oils as the source of PUFAs, whereas observational
studies showing favorable associations evaluated replace-
ment of saturated fat or carbohydrate with PUFA intake.
These diverse potential sources suggest that other compo-
nents present in less healthy food sources might be
counterbalancing potential beneﬁcial effects of ALA and LA.
Our study has important strengths. The use of both
circulating PUFA biomarkers and dietary estimates provided a
comprehensive evaluation of the relationships of interest,
including exposures with different and complementary
strengths, limitations, and sources of bias. The prospective
cohort design minimized recall and selection bias and allowed
inference on temporality of associations. Adjustment for a
variety of demographic, lifestyle, and other risk factors
minimized the potential for confounding. Finally, the multi-
ethnic nature of the cohort allowed separate evaluations of
different race/ethnic groups and increased the generalizabil-
ity of our ﬁndings.
Potential limitations should be considered. Cross-sectional
associations with cardiovascular risk factors could be limited
by reverse causation, yet several of these associations were
consistent with the demonstrated effects of n-3 and n-6
PUFA in prior metabolic studies, as well as with prospective
analysis of CVD events in our study. Imprecision in
measurement of both circulating and dietary PUFAs may
result in exposure misclassiﬁcation, attenuating measures of
association toward the null. Thus, our ﬁndings could have
underestimated the true associations. Finally, although we
carefully adjusted for several potential confounders, we
cannot exclude the possibility of residual confounding.
Nevertheless, our observed associations were robust to
adjustment for a range of major potential risk factors.
In conclusion, we found an inverse associations of seafood-
derived long-chain n-3 PUFAs, but not plant-derived n-3 or n-6
PUFAs, with CVD incidence in a multiethnic cohort. These
ﬁndings suggest that increased consumption of n-3 PUFAs
from seafood may prevent CVD development in multiethnic
populations.
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